By blocking TGF-β signaling, the nano-regulator aimed to reverse the immunosuppressive effects and restore immune sensitivity in bone metastatic tumors, potentially enhancing the body’s ability to combat cancer cells in that specific setting. This evidence concerns the gene TGFB1 and cancer.